Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Leitzel

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Predicting response to herceptin therapyAllan Lipton, Kim Leitzel, Suhail Ali
Current Osteoporosis Reports|January 11, 2015
Antiresorptive therapy in the management of cancer treatment-induced bone lossAshwani Garg, Kim Leitzel, Suhail Ali, et al.
Breast Cancer Research : BCR|June 15, 2007
HER-2/neu diagnostics in breast cancerWalter P Carney, Kim Leitzel, Suhail Ali, et al.
International Journal of Oncology|January 16, 2003
Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCRLoren E Clarke, Kim Leitzel, Jill Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trialsSuhail M Ali, Kim Leitzel, Allan Lipton, et al.
Clinical Chemistry|September 23, 2003
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Clinical Breast Cancer|July 13, 2004
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Cancers|July 30, 2020
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone MetastasesSoraia Lobo-Martins, Arlindo R Ferreira, André Mansinho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Serum osteoprotegerin levels in healthy controls and cancer patientsAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Cancer|April 5, 2007
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancerAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Predicting response to herceptin therapyAllan Lipton, Kim Leitzel, Suhail Ali
Current Osteoporosis Reports|January 11, 2015
Antiresorptive therapy in the management of cancer treatment-induced bone lossAshwani Garg, Kim Leitzel, Suhail Ali, et al.
Breast Cancer Research : BCR|June 15, 2007
HER-2/neu diagnostics in breast cancerWalter P Carney, Kim Leitzel, Suhail Ali, et al.
International Journal of Oncology|January 16, 2003
Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCRLoren E Clarke, Kim Leitzel, Jill Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trialsSuhail M Ali, Kim Leitzel, Allan Lipton, et al.
Clinical Chemistry|September 23, 2003
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Clinical Breast Cancer|July 13, 2004
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Cancers|July 30, 2020
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone MetastasesSoraia Lobo-Martins, Arlindo R Ferreira, André Mansinho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Serum osteoprotegerin levels in healthy controls and cancer patientsAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Cancer|April 5, 2007
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancerAllan Lipton, Suhail M Ali, Kim Leitzel, et al.
Pageof 4